Format

Send to

Choose Destination
Indian J Cancer. 2015 Jul-Sep;52(3):449-52. doi: 10.4103/0019-509X.176732.

Treatment of patients with metastatic pancreatic cancer: Experience from a tertiary Indian cancer center.

Author information

1
Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.

Abstract

BACKGROUND:

The aim of this study was to look at the outcome of patients with metastatic pancreatic cancer treated at a tertiary cancer center in India.

PATIENTS AND METHODS:

A total of 101 patients with locally advanced and metastatic pancreatic cancer diagnosed between May 2012 and July 2013 were identified from a prospectively maintained database at the tertiary cancer center. Overall survival (OS) was computed using the Kaplan-Meir product limit method and compared across groups using the log-rank statistics. Cox proportional hazards model, adjusted for a number of patient and tumor characteristics, was then used to determine factors prognostic for OS.

RESULTS:

Median age at diagnosis was 55 years (range: 21-81 years). 57.4% (n = 58) of patients were male, 22% (n = 22) had performance status (PS) of <2 at diagnosis and 89% received first-line chemotherapy, while the rest received best supportive care. For the whole cohort, 6 month and 1-year OS was 57% (95% confidence interval [CI]: 46-66%) and 47% (95% CI: 35-57%), respectively. In a multivariable model, PS <2 and oligometastatic disease were associated with a significantly decreased risk of death.

CONCLUSION:

Results from our analysis indicate that the prognostic outcome among Indian patients with metastatic pancreatic cancer is poor with survival outcomes similar to those reported in North America and Europe.

PMID:
26905166
DOI:
10.4103/0019-509X.176732
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center